Knight Therapeutics (OTCMKTS:KHTRF) Trading Up 1% – Here’s Why

Knight Therapeutics Inc. (OTCMKTS:KHTRF) shares were up 1% on Thursday . The company traded as high as $6.05 and last traded at $6.05. Approximately 3,000 shares traded hands during mid-day trading, a decline of 59% from the average daily volume of 7,284 shares. The stock had previously closed at $5.99.

Wall Street Analyst Weigh In

Separately, Royal Bank Of Canada reiterated an “outperform” rating on shares of Knight Therapeutics in a report on Friday, May 8th. One investment analyst has rated the stock with a Buy rating, According to data from MarketBeat.com, the company currently has an average rating of “Buy”.

Knight Therapeutics Trading Up 1.0%

The company’s fifty day moving average is $5.70 and its two-hundred day moving average is $4.85.

Knight Therapeutics Company Profile

Knight Therapeutics Inc (OTCMKTS:KHTRF) is a specialty pharmaceutical company headquartered in Montreal, Canada, focused on acquiring, in-licensing and commercializing innovative branded products for the Canadian and Latin American markets. The company secures exclusive marketing and distribution rights to medicines across multiple therapeutic areas, including ophthalmology, pain management, hematology and women’s health. Its portfolio features both prescription pharmaceuticals and specialty products that address unmet patient needs through targeted treatments.

Operating primarily in Canada, Mexico and select Latin American countries, Knight has established strategic alliances with global pharmaceutical firms to introduce novel therapies at various stages of development.